Phase 2 Trial of Retifanlimab (anti-PD-1) in Combination With INCAGN02385 (anti-LAG-3) and INCAGN02390 (anti-TIM-3) as First-Line Treatment in Patients With PD-L1-Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
INCAGN-02385;INCAGN-02390;Retifanlimab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 2 Trial of Retifanlimab (anti-PD-1) in Combination With INCAGN02385 (anti-LAG-3) and INCAGN02390 (anti-TIM-3) as First-Line Treatment in Patients With PD-L1-Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck ### Output: INCAGN-02385;INCAGN-02390;Retifanlimab